Process For The Preparation Of Drospirenone

Abstract

A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action; comprising the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol.

1 . Process for the preparation of drospirenone, comprising the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol of formula (VIII) with a suitable oxidising agent in an organic solvent in the presence of a catalytic amount of the 2,2,6,6-tetramethylpiperidine-1-oxyl radical or a derivative thereof, said oxidation being followed by the addition of a protic acid directly into the same container in which the oxidation took place, to obtain the drospirenone of formula (I) 
       
         
           
           
               
               
           
         
       
     
     
         2 . The process according to  claim 1 , wherein said 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol of formula (VIII) is prepared starting from 5,6β-epoxy-7β-hydroxy-15β,16β-methylene-3β-pivaloyloxy-5β-androstan-17-one of formula (II) in accordance with the following steps:
 a) bromination in position 7α of 5,6β-epoxy-7β-hydroxy-15β,16β-methylene-3β-pivaloyloxy-5β-androstan-17-one of formula (II) to obtain 7α-bromo-5,6β-epoxy-15β,16β-methylene-3-pivaloyloxy-5β-androstan-17-one of formula (III) by reacting the compound of formula (II) with mesyl chloride to obtain the corresponding mesylate which is not isolated and from which the compound of formula (III) is obtained by adding lithium bromide:   
       
         
           
           
               
               
           
         
       
       in which the symbol PV indicates a pivaloyl group, i.e. a trimethylacetyl group;
 b) opening the epoxy ring and removing the bromine from 7α-bromo-5,6β-epoxy-15β,16β-methylene-3β-pivaloyloxy-5β-androstan-17-one of formula (III) derived from step a) to obtain the 5-hydroxy-15β,16β-methylene-3β-pivaloyloxy-5β-androst-6-en-17-one of formula (IV): 
 
       
         
           
           
               
               
           
         
         c) hydrolysis of the pivaloyl group of 5-hydroxy-15β,16β-methylene-3-pivaloyloxy-5β-androst-6-en-17-one of formula (IV) coming from step b) to obtain the 3β,5-dihydroxy-15β,16β-methylene-5β-androst-6-en-17-one of formula (V): 
       
       
         
           
           
               
               
           
         
       
       in which PV is defined as above,
 d) methylenation at the Δ 6  double bond of 3β,5-dihydroxy-15β,16β-methylene-5β-androst-6-en-17-one of formula (V) coming from step c) to obtain the 3β,5-dihydroxy-6β,7β;15β,16β-dimethylene-5β-androst-17-one of formula (VI) 
 
       
         
           
           
               
               
           
         
         e) reacting the 3β,5-dihydroxy-6β,7β;15β,16β-dimethylene-5β-androst-17-one of formula (VI) coming from step d) with propargyl alcohol to obtain the 17α-(3-hydroxy-1-propinyl)-6β,7β;15β,16β-dimethylene-5β-androstane-3β,5,17β-triol of formula (VII) 
       
       
         
           
           
               
               
           
         
         f) hydrogenating the 17α-(3-hydroxy-1-propinyl)-6β,7β;15β,16β-dimethylene-5β-androstane-3β,5,17β-triol of formula (VII) coming from step e) to obtain the 17α-(3-hydroxypropyl)-6β,7β;15β,16β-dimethylene-5β-androstane-3β,5,17β-triol of formula (VIII) 
       
       
         
           
           
               
               
           
         
       
     
     
         3 . The process according to  claim 1 , wherein said oxidising agent is selected from the group consisting of alkali metal and alkaline-earth metal hypohalides, iodine, oxygen in the presence of CuCl, potassium peroxymonosulphate and 1,3,5-trichloro-2,4,6-triazinetrione. 
     
     
         4 . The process according to  claim 3 , wherein said oxidising agent is selected from sodium hypochlorite and calcium hypochlorite. 
     
     
         5 . The process according to  claim 1 , wherein said derivative of the 2,2,6,6-tetramethylpiperidine-1-oxyl radical is selected from the group consisting of the 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl radical, the 4-methoxy-2,2,6,6-tetramethylpiperidine-1-oxyl radical and the 4-(benzoyloxy)-2,2,6,6-tetramethylpiperidine-1-oxyl radical. 
     
     
         6 . The process according to  claim 1 , wherein said organic solvent is selected from the group consisting of ethers, esters, hydrocarbons, halogenated hydrocarbons and mixtures thereof. 
     
     
         7 . The process according to  claim 1 , wherein said organic solvent is selected from the group consisting of acetone, toluene, methyl t-butyl ether, ethyl acetate, methylene chloride, tetrahydrofuran and mixtures thereof. 
     
     
         8 . The process according to  claim 1 , wherein said oxidation is carried out at a temperature between 0 and 40° C. 
     
     
         9 . The process according to  claim 1 , wherein said oxidation is carried out with calcium hypochlorite using as organic solvent a methylene chloride/tetrahydrofuran mixture at a temperature between 20 and 25° C. in the presence of a catalytic amount of the 2,2,6,6-tetramethylpiperidine-1-oxyl radical and in the presence of an aqueous sodium bicarbonate solution. 
     
     
         10 . The process according to  claim 9 , wherein said methylene chloride/tetrahydrofuran mixture is used in a ratio of 8.5/1. 
     
     
         11 . The process according to  claim 1 , wherein said protic acid is selected from the group consisting of concentrated hydrochloric acid, dilute hydrochloric acid and p-toluenesulfonic acid. 
     
     
         12 . The process according to  claim 11 , wherein said protic acid is p-toluenesulfonic acid monohydrate. 
     
     
         13 . The process according to  claim 1 , wherein said protic acid addition is carried out at a temperature between 0 and 40° C. 
     
     
         14 . The process according to  claim 13 , wherein said protic acid addition is carried out at a temperature between 20 and 25° C. 
     
     
         15 . The process according to  claim 1 , wherein said protic acid is added directly to the organic solution in which the oxidation reaction took place. 
     
     
         16 . The process according to  claim 1 , wherein said protic acid is added to the solution obtained by dissolving in a suitable organic solvent the semi-solid residue coming from the distillation of the organic solution in which the oxidation reaction took place. 
     
     
         17 . The process according to  claim 2 , wherein said bromination reaction in step a) is carried out by adding mesyl chloride and pyridine to the starting compound at room temperature with the formation of the corresponding mesylate, then adding lithium bromide dissolved in water and bringing the temperature to values between 70 and 75° C. 
     
     
         18 . The process according to  claim 1 , further comprising purification of the crude drospirenone by a procedure comprising gel filtration and filtrate crystallisation from organic solvent, said procedure possibly being repeated one or more times. 
     
     
         19 . The process according to  claim 18 , wherein said purification comprises the following steps:
 i) dissolving crude drospirenone in a suitable organic solvent, further containing silica gel and decolourising carbon, and filtering the solution thus obtained;   ii) distilling the solution coming from step i) and redissolving the distillate in a second organic solvent;   iii) distilling the solution coming from step ii) and redissolving the distillate in said second organic solvent;   iv) crystallising pure drospirenone from the solution coming from step iii);   v) recovering pure drospirenone by filtering, washing over the filter at least once with a suitable organic solvent, and drying at a pressure lower than atmospheric pressure;   vi) optionally repeating steps i) to v), starting from the drospirenone coming from step v).   
     
     
         20 . The process according to  claim 19 , wherein the amount of silica gel and decolourising carbon utilised is less than 5% by weight with respect to the weight of the crude drospirenone to be purified. 
     
     
         21 . The process according to  claim 19 , wherein the distillation temperature in steps ii) and iii) is between 35 and 45° C. 
     
     
         22 . The process according to  claim 19 , wherein said distillation in steps ii) and iii) is carried out at a pressure lower than atmospheric pressure. 
     
     
         23 . The process according to  claim 19 , wherein said crystallisation in step iv) is carried out at a temperature between 0 and 50° C. for a time period between 60 and 180 minutes. 
     
     
         24 . The process according to  claim 19 , wherein said organic solvent in steps i), ii), iii) and v) is selected from the group consisting of ethyl ether, isopropyl ether, ethyl acetate, methyl tertbutyl ether, isopropyl acetate, methyl acetate, dimethoxyethane, methanol, ethanol, isopropanol, methylene chloride, acetone, dimethylacetamide, dimethylformamide and mixtures thereof. 
     
     
         25 . The process according to  claim 19 , wherein said organic solvent in step i) is methylene chloride, said organic solvent in step ii) is isopropyl acetate, and in step v) two washings are carried out, the first with isopropyl acetate and the second with ethyl ether. 
     
     
         26 . Drospirenone having purity higher than 96.5%, obtained by oxidation of compound of formula (VIII) as defined in  claim 1 , in an organic solvent, in the presence of a catalytic amount of 2,2,6,6-tetramethylpiperidine-1-oxyl radical or a derivative thereof, and addition of aprotic acid. 
     
     
         27 . Drospirenone having purity higher than 99.5%, obtained by purification of the product obtained by the process as defined in  claim 1 , by gel filtration and filtrate crystallisation from organic solvent, without subjecting the product to any chromatographic procedure. 
     
     
         28 . A pharmaceutical composition comprising drospirenone as defined in  claim 26  as active principle, and a carrier. 
     
     
         29 . A pharmaceutical composition comprising drospirenone as defined in  claim 27  as active principle, and a carrier.